The FDA approved trastuzumab-pkrb (Herzuma, Celltrion/Teva), a HER2/neu receptor antagonist biosimilar to trastuzumab (Herceptin, Genentech) for breast cancer treatment.
The new biosimilar is indicated:
- for adjuvant breast cancer of HER2 overexpressing node-positive or -negative (estrogen/progesterone-negative or with one high-risk feature) breast cancer;
- as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel;
- as part of a